tirzepatide sydney FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price Tirzepatide Weight Loss Injections in

The US Food and Drug Administration approved this first-in-class medication for the management of type 2 diabetes (T2D) in 2022 [2], for the reduction of excess weight in adults with obesity or overweight in 2023 [3], and for moderate-to-severe obstructive sleep apnea (OSA) in people with obesity in 2024 [4]

Assessment for obstructive sleep apnoea OSA is a condition characterised by repetitive obstruction of the upper airway during sleep, resulting in partial cessation (hypopnoea) or total cessation (apnoea) of breathing, reduced blood oxygen saturation and sleep disturbance

Along with weight reduction, patients often experience improvements in blood sugar control, blood pressure, and lipid profiles, contributing to a lower risk of cardiovascular events, a major concern for individuals with obesity

2023;18(5): e0285197

2023;72(Suppl 1):129-OR